Product Description: CBPD-268 is a potent and orally active CBP/p300 PROTAC degrader with an DC50 value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Srtucture Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker)[1].
Formula: C44H47F2N9O5
References: [1]Chen Z, et al. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression. J Med Chem. 2024 Apr 11;67(7):5275-5304.
Molecular Weight: 819.90
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Histone Acetyltransferase;PROTACs